Investec Bank Plc (INVP.L, INL.JO) purchased 37,174 ordinary shares in Advanced Medical Solutions Group Plc (AMS.L) on 6 November 2026, regulatory filings confirm.
The transaction was executed within a tight price range, with the highest amount paid reaching 283.1 pence per unit and the lowest sitting at 282.55 pence per share.
The narrow spread between the top and bottom prices signals a relatively stable trading environment for Advanced Medical Solutions shares on the day of the transaction.
Investec holds a dual role in relation to the deal, serving simultaneously as financial adviser and joint broker to Advanced Medical Solutions Group Plc throughout the ongoing offer process.
That dual capacity requires the bank to file public disclosures under Rule 8.5 of the UK Takeover Code whenever it trades in the relevant securities in a client-serving capacity.
The filing, submitted on 9 November 2026, classifies Investec as an exempt principal trader operating with recognised intermediary status, a designation that carries specific transparency obligations under the Code.
No derivative transactions of any kind were recorded alongside the share purchase, with cash-settled, stock-settled, and all other dealing categories returning not applicable in the disclosure.
Investec also confirmed the absence of any indemnity arrangements, option agreements, or understandings that could constitute an inducement to deal or to withhold from dealing.
Similarly, no agreements relating to voting rights, future acquisitions, or disposals connected to any derivative instruments were reported, leaving the ordinary share purchase as the sole disclosed activity.
The disclosure was filed with a Regulatory Information Service in accordance with requirements set by the Takeover Panel, which oversees compliance with dealing transparency rules during offer periods.
Advanced Medical Solutions Group Plc, a specialist medical device and wound care company, has been subject to the heightened disclosure regime that accompanies formal offer activity under the Code.
The contact listed on the regulatory filing is Abhishek Gawde, reachable by telephone, with the Takeover Panel’s Market Surveillance Unit separately available to handle queries regarding dealing disclosure obligations.
